NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.

Mutant RAS oncoproteins activate signaling molecules that drive oncogenesis in multiple human tumors including acute myelogenous leukemia (AML). However, the specific functions of these pathways in AML are unclear, thwarting the rational application of targeted therapeutics. To elucidate the downstream functions of activated NRAS in AML, we used a murine model that harbors Mll-AF9 and a tetracycline-repressible, activated NRAS (NRAS(G12V)). Using computational approaches to explore our gene-expression data sets, we found that NRAS(G12V) enforced the leukemia self-renewal gene-expression signature and was required to maintain an MLL-AF9- and Myb-dependent leukemia self-renewal gene-expression program. NRAS(G12V) was required for leukemia self-renewal independent of its effects on growth and survival. Analysis of the gene-expression patterns of leukemic subpopulations revealed that the NRAS(G12V)-mediated leukemia self-renewal signature is preferentially expressed in the leukemia stem cell-enriched subpopulation. In a multiplexed analysis of RAS-dependent signaling, Mac-1(Low) cells, which harbor leukemia stem cells, were preferentially sensitive to NRAS(G12V) withdrawal. NRAS(G12V) maintained leukemia self-renewal through mTOR and MEK pathway activation, implicating these pathways as potential targets for cancer stem cell-specific therapies. Together, these experimental results define a RAS oncogene-driven function that is critical for leukemia maintenance and represents a novel mechanism of oncogene addiction.

[1]  Jeffrey A. Magee,et al.  Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness , 2013, Nature.

[2]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[3]  P. Chevallier,et al.  A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse , 2013, Leukemia.

[4]  D. Campana,et al.  Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. , 2012, Blood.

[5]  K. Shannon,et al.  Targeting oncogenic Ras signaling in hematologic malignancies. , 2012, Blood.

[6]  C. So,et al.  Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/&bgr;-catenin pathway , 2012, Current opinion in hematology.

[7]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[8]  S. Armstrong,et al.  Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. , 2012, Cell stem cell.

[9]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[10]  D. Bar-Sagi,et al.  Regulating the regulator: post-translational modification of RAS , 2011, Nature Reviews Molecular Cell Biology.

[11]  A. Vekhoff,et al.  Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. , 2011, Blood.

[12]  Sean C. Bendall,et al.  Extracting a Cellular Hierarchy from High-dimensional Cytometry Data with SPADE , 2011, Nature Biotechnology.

[13]  T. Graeber,et al.  An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. , 2011, Genes & development.

[14]  E. Ranheim,et al.  Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. , 2011, Blood.

[15]  Sean C. Bendall,et al.  Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum , 2011, Science.

[16]  T. Jacks,et al.  Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. , 2011, Blood.

[17]  Ash A. Alizadeh,et al.  Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. , 2010, JAMA.

[18]  C. So,et al.  β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. , 2010, Cancer cell.

[19]  M. Cleary,et al.  Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells? , 2010, International journal of hematology.

[20]  Cole Trapnell,et al.  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.

[21]  Wolfram Goessling,et al.  The Wnt/β-Catenin Pathway Is Required for the Development of Leukemia Stem Cells in AML , 2010, Science.

[22]  J. Downing,et al.  Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia , 2009, Proceedings of the National Academy of Sciences.

[23]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[24]  Howard Y. Chang,et al.  Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. , 2009, Cell stem cell.

[25]  D. Largaespada,et al.  RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia. , 2009, Blood.

[26]  Yiguo Hu,et al.  Beta-catenin Is Essential for Survival of Leukemia Stem Cells Insensitive to Kinase Inhibition in Mice with BCR-ABL Induced Chronic Myeloid Leukemia. , 2008 .

[27]  Jonathan M Irish,et al.  Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. , 2008, Cancer cell.

[28]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[29]  K. Shannon,et al.  Targeting Ras in Myeloid Leukemias , 2008, Clinical Cancer Research.

[30]  T. Reya,et al.  Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo , 2007 .

[31]  J. Downing,et al.  Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias , 2007, Leukemia.

[32]  T. Golub,et al.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.

[33]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Largaespada,et al.  Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse. , 2005, Blood.

[35]  J. Downing,et al.  Gene Expression Profiling of Pediatric Acute Myelogenous Leukemia Materials and Methods , 2022 .

[36]  I. Weissman,et al.  Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. , 2003, Genes & development.

[37]  M. Cleary,et al.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. , 2003, Genes & development.

[38]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[39]  D. Pattabiraman,et al.  Role and potential for therapeutic targeting of MYB in leukemia , 2013, Leukemia.

[40]  E. Ranheim,et al.  MYELOID NEOPLASIA NrasG 12 D / 1 promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions , 2013 .

[41]  K. Inokuchi,et al.  Acute Leukemia : Update of Clinical Aspects , 2010 .

[42]  Shaoguang Li,et al.  β-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia , 2009, Leukemia.

[43]  J. Tamburini,et al.  Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. , 2008, Blood.

[44]  I. Weissman,et al.  Establishment of a normal hematopoietic and leukemia stem cell hierarchy. , 2008, Cold Spring Harbor symposia on quantitative biology.

[45]  T. Reya,et al.  Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. , 2007, Cancer cell.